Drug Channels: Walmart, Walgreens dominate 2015 Medicare Part D preferred networks
PHILADELPHIA — Drug Channels on Tuesday released a report showing that Walmart and Walgreens dominate 2015 Medicare Part D preferred networks, followed by independent pharmacy.
"Walmart again leads the pack in preferred network participation," wrote Adam Fein, president of Pembroke Consulting and writer of the Drug Channels blog. "Walgreens has a big bet on preferred networks, while CVS and Rite Aid have been more cautious. Independent pharmacies feature prominently in many plans, which should — but probably won't — mute critics of preferred networks."
Based on online plan summary information, Drug Channels developed a table that summarizes the top seven retail pharmacy chains’ participation in major preferred networks.
Survey: Millennials worry about their health as much as Boomers
NEW YORK — Adult millennials ages years 18 to 32 years worry about their health and access to health care as much as their baby boomer elders, according to a survey conducted by Allidura Consumer and GSW, both part of inVentiv Health, and Harris Poll.
“As society shifts its focus from relying on HCPs to treat disease to taking individual responsibility for prevention and wellness, we wanted to understand how attuned millennials are to their health now, and how it factors into their everyday decision making,” said Tracy Naden, managing director of Allidura Consumer. “What we learned is that millennials’ mindset about health is very much an ever present personal journey of wellness fueled by food, exercise and social connections.”
The survey report, “Millennial Mindset: The Worried Well,” notes that as creators of the quantified-self movement, millennials are often perceived as healthier than their boomer counterparts. Yet, one commonality this generation may not have expected at such an early stage of adulthood is that they worry about their health almost exactly as much as boomers (77% of both generations say they worry at least a little about getting a serious illness; 77% of adult millennials and 74% of boomers say they worry at least a little about affording the cost of healthcare). In fact, millennial adults worry about their access to health care even more than boomers (69% vs. 60% worry at least a little).
The study suggests that millennials see the mind-body connection as important to overall health. With 69% of millennials reporting they stress about their personal health, it seems many are beginning to prioritize mental well-being as a key factor to physical health. In fact, survey results show that 35% of millennials believe seeing a therapist or psychiatrist regularly is important to good health. Millennials are the first generation to grow up with “doctor Google” at their fingertips. According to Derek Flanzraich, CEO of Greatist.com, a popular health-and-wellness website for millennials, “There's never been more health information for millennials to find, so it only makes sense that it's never been more difficult for them to properly screen, analyze and act on the right data.”
This is supported by survey data that finds 37% of millennials sometimes self-diagnose with health problems that they don’t have. Perpetuating this “search and stress” cycle, 44% say that viewing health information online causes them to worry about their health. “For millennials, the question isn’t who can help them be healthy, but rather what can help them,” said Leigh Householder, chief innovation officer at GSW. “To millennials, physical health is intricately connected with mental health. So, for brand marketers to be successful in reaching this audience, they must think about health and wellness the same way, and create solutions that inspire millennials to experience health at any given moment and throughout all aspects of their lives.”
The online survey included responses from 3,530 teens and adults, including 2,015 adult millennials.
Amneal Pharmaceuticals named ‘Company of the Year’
BRIDGEWATER, N.J. — Amneal Pharmaceuticals on Tuesday announced that the company has won the global “Company of the Year" Award from Generics bulletin, a newsletter which provides commercial and regulatory information for the global generics and biosimilars industries. Presented on Oct. 7 at the Global Generics & Biosimilars Awards 2014 held in Paris, France, the award recognizes Amneal’s rapid growth in North America.
Amneal is the 7th largest U.S. generics manufacturer based on prescriptions dispensed, according to IMS Health. The company’s 76 Food and Drug Administration-approved generic medications and pipeline of 264 products filed with the FDA or in development cover a broad range of therapeutic categories. In addition to high-volume commodity medicines, Amneal’s portfolio contains many high-barrier-to-entry and difficult-to-formulate products and spans almost the entire range of dosage forms in the market.
The company will spend more than $400 million on R&D and capital improvements to its nine manufacturing plants in the U.S. and India over the next two years. Amneal has also invested considerable resources in human capital as well as product development and now employs over 2,600 worldwide.
In addition to its U.S. operations, Amneal is expanding internationally by establishing front-end marketing and distribution capabilities in the U.K., Spain, Germany, the Nordic countries, Switzerland and Australia. The company is also pursuing acquisitions and evaluating strategic partners in Japan, Southeast Asia and Latin America.
“We are deeply honored to be recognized as global ‘Company of the Year’,” said Amneal Co-CEO and Co-Chairman Chirag Patel. “This award lets us know we’re doing all the right things to run a successful, growing enterprise while remaining true to our values – dedication to quality across all operations, maintaining our high standards and ethics and total commitment to our customers, partners and employees.”
Loading Post Please Wait...